At a glance
ClinicalIndex Comparison Record- ✓Age greater than 18 years
- ✓Triple Negative Breast Cancer Stage IV without prior systemic therapy in metastatic setting, or Stage I-III with residual mass after neoadjuvant chemotherapy
- ✓Stage IV colorectal cancer with ≤1 line of systemic therapy in metastatic setting, undergoing liver resection or with biopsyable lesions
- ✓Advanced High Grade Serous Ovarian Cancer with recurrent disease (≥12 month life expectancy) or Stage III-IV with residual disease after neoadjuvant chemotherapy
- ✕Clinically significant hepatic, renal, cardiac or other organ dysfunction likely to limit trial participation
- ✕Known brain metastasis
- ✕Conditions interfering with informed consent ability such as dementia or severe cognitive impairment
- ✕Contraindication to biopsy procedure
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host
In Brief
An observational study evaluating Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures for Colorectal Neoplasms and 5 related conditions. Currently recruiting, targeting 120 participants across 1 site.
Detailed Summary
By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options
Study Details
Timeline
Interventions
Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.